शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
THEMISMEDNSETHEMIS MEDICARE LTD.· Pharmaceuticals & BiotechnologyHighNegative
Announced Thu, 24 Sept, 2026 · 19:45 IST

Themis Medicare withdraws proposed preferential warrant issue

THEMISMED · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.9%Reaction day
₹117.53
prior close
₹119.90
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.3%-1.2% vs market
Pharmaceuticals peers, median of 171sector-0.0%-0.8% vs sector

On the reaction day the stock moved 1.2 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.9
10m
-2.4
15m
-2.2
30m
-2.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.9+0.3-1.2-0.0-0.8
Next day
-1.0-1.3+0.3-1.3+0.4
2d
+1.9-0.3+2.2-0.6+2.5
3d
-0.9-0.6-0.3-1.7+0.8
4d
-3.6-1.8-1.8-2.5-1.2
5d
-2.5-1.8-0.7-2.7+0.1
1w
-2.7-0.8-2.0-2.2-0.5
15d
-14.7-4.1-10.5-6.0-8.7
1m
-22.4-9.4-13.0-9.1-13.3
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Themis Medicare has withdrawn its proposed preferential issue of 45,95,795 convertible equity warrants to a promoter group entity at Rs. 102.87 per warrant. Originally approved on Feb 25, 2026, the issue aimed to meet working capital needs, which have now been arranged through other means. The company will also withdraw its in-principal approval applications from BSE and NSE. Management states no adverse impact on financials or operations.

Likely market impact

No equity dilution now; working capital needs met via other routes. No adverse impact stated by management.